BIXT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 03:35):

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans...

Stats
今日成交量	91 490.00
平均成交量	106 849
市值	15.85M
EPS	$-0.00734 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.65
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Milanova Radka	Buy	70 423	common
2024-04-19	Conaway Dale H	Buy	70 423	common
2024-04-19	Hoberman Alan M	Buy	70 423	common
2024-04-19	Milanova Radka	Sell	0	common
2024-03-27	Utter Anders	Buy	266 955	common

INSIDER POWER
89.94
Last 84 transactions
Buy: 33 376 843 \| Sell: 11 429 961

Bioxytran, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Bioxytran, Inc. 财务报表

Annual	2022
营收:	$0
毛利润:	$-3 644.00 (0.00 %)
EPS:	$-0.0214

FY	2022
营收:	$0
毛利润:	$-3 644.00 (0.00 %)
EPS:	$-0.0214

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0420

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0271

Financial Reports:

No articles found.

Bioxytran, Inc.

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.